-
DATA AT EASD SUGGESTS BETTER GLYCAEMIC CONTROL POSSIBLE USING INSULIN GLARGINE OR INSULIN GLULISINE IN TYPE 2 DIABETES
-
Strong growth in 2005 first half adjusted EPS : up 26.1% at 2.22
-
A high proportion of hypertensive patients achieved blood pressure treatment goal with irbesartan-based combination therapy, findings show
-
DATA PRESENTED AT AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS SUPPORT EXUBERA EFFICACY AND SAFETY PROFILE IN TYPE 1 A AND TYPE 2 DIABETES
-
2005 first-quarter net sales growth ahead of world pharmaceutical
-
2004 pro forma combined net sales up 10.0% on a comparable basis
